ARTL
NASDAQArtelo Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.74-7.34 (-72.82%)
2026-07-162026-10-16
News · 26 weeks48-25%
2026-04-192026-10-11
Mix2190d
- Other11(52%)
- Insider6(29%)
- SEC Filings4(19%)
Latest news
25 items- SECSEC Form 8-K filed by Artelo Biosciences Inc.8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformPresentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio SOLANA BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it has been selected to deliver a company presentation at BIO-Europe 20
- PRArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical FindingsAs reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030 New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focu
- PRArtelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of ObesityOnce-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a "metabolic regulator" capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLANA BEACH, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling
- PRArtelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte New York Palace Hotel in New York City. Artelo’s presentation will be available on September 11, 2026 at 7:00 a.m. Eastern Time and can be accessed here: https://journey.ct.events/vie
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Announces Reverse Stock SplitSOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split ("Reverse Split") of the Company’s common stock ("Common Stock"). The Company’s Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open on August 31, 2026. The Reverse Split is being effected in order to increase the price per share of the Common Stock to improve its marketabi
- SECAmendment: SEC Form 10-Q/A filed by Artelo Biosciences Inc.10-Q/A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial formulation of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. The allowed claims in Japan protect compositions of ART27.13
- PRArtelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 StudiesThe Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently being evaluated in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Artelo Biosciences Inc.SCHEDULE 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
- PRArtelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial ResultsSOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the second quarter ended June 30, 2026. Business Highlights ART26.12: Advancing Toward Multiple-Dose Clinical Evaluation: Artelo continues preparations to initiate a Phase 1 multiple ascending dose study in the fourth quarter of 2026. First-in-human data showed favorable safety and tolerabil
- SECSEC Form 10-Q filed by Artelo Biosciences Inc.10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of GlaucomaInvestigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology Initial DREAM Study Results Anticipated in Q4 2026 SOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the first patient has been dosed in the DREAM study (Determining the Role of synthetic cannabinoids in Eye pressure And tolerability Measurements), which will evaluate the effects of Artelo’s orally administered synt
- PRNew Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD CompositionReview Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article titled, "Evaluating th
- INSIDERSEC Form 4 filed by Director Matsui Connie4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- INSIDERSEC Form 4 filed by Director Blayney Douglas4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- INSIDERSEC Form 4 filed by Director Reyes Gregory4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- INSIDERSEC Form 4 filed by Director Emanuele Robert Martin4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelly Steven4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- INSIDERSEC Form 4 filed by Director Favorito Tamara A4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain ConditionsSOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Re
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
ARTL FAQ
6 questionsWhat does Artelo Biosciences Inc. do?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for...Where does ARTL stock trade?
Artelo Biosciences Inc. (ARTL) is listed on NASDAQ.What sector and industry is ARTL in?
Artelo Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ARTL?
Artelo Biosciences Inc. has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $2000.00 price target on 2025-07-08. Recent price targets range from $400.00 to $2000.00.What companies are similar to ARTL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARTL side-by-side with any of them on Quantisnow.How can I track ARTL on Quantisnow?
Quantisnow aggregates Artelo Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTL to receive live email and push alerts on every new disclosure.